Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Uncovering the association between fatigue and fatigability in multiple sclerosis using cognitive control.

Cehelyk EK, Harvey DY, Grubb ML, Jalel R, El-Sibai MS, Markowitz CE, Berger JR, Hamilton RH, Chahin S.

Mult Scler Relat Disord. 2019 Jan;27:269-275. doi: 10.1016/j.msard.2018.10.112. Epub 2018 Oct 27.

PMID:
30423531
2.

Limbic pathway lesions in patients with multiple sclerosis.

Sahin N, Selouan R, Markowitz CE, Melhem ER, Bilello M.

Acta Radiol. 2016 Mar;57(3):341-7. doi: 10.1177/0284185115578689. Epub 2015 Apr 6.

PMID:
25852192
3.

Identifying and addressing unmet therapeutic needs in MS.

Markowitz CE.

J Clin Psychiatry. 2015 Mar;76(3):e8. doi: 10.4088/JCP.13037nr4c.

4.

Switching therapies in MS: what are the options?

Markowitz CE.

J Clin Psychiatry. 2015 Feb;76(2):e6. doi: 10.4088/JCP.13037nr2c. Review. No abstract available.

5.

Re-evaluating the treatment of acute optic neuritis.

Bennett JL, Nickerson M, Costello F, Sergott RC, Calkwood JC, Galetta SL, Balcer LJ, Markowitz CE, Vartanian T, Morrow M, Moster ML, Taylor AW, Pace TW, Frohman T, Frohman EM.

J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):799-808. doi: 10.1136/jnnp-2014-308185. Epub 2014 Oct 29. Review.

6.

Multiple sclerosis update.

Markowitz CE.

Am J Manag Care. 2013 Nov;19(16 Suppl):s294-300. Review.

7.

Constructing an adaptive care model for the management of disease-related symptoms throughout the course of multiple sclerosis--performance improvement CME.

Miller AE, Cohen BA, Krieger SC, Markowitz CE, Mattson DH, Tselentis HN.

Mult Scler. 2014 Jan;20(1):18-23. doi: 10.1177/1352458513495937. Epub 2013 Aug 6.

PMID:
23921134
8.

Direct visualization of short transverse relaxation time component (ViSTa).

Oh SH, Bilello M, Schindler M, Markowitz CE, Detre JA, Lee J.

Neuroimage. 2013 Dec;83:485-92. doi: 10.1016/j.neuroimage.2013.06.047. Epub 2013 Jun 22.

9.

Exposure to CYP3A4-inducing and CYP3A4-non-inducing antiepileptic agents and the risk of fractures.

Schelleman H, Pollard JR, Newcomb C, Markowitz CE, Bilker WB, Leonard MB, Hennessy S.

Pharmacoepidemiol Drug Saf. 2011 Jun;20(6):619-25. doi: 10.1002/pds.2141.

10.

Stratus OCT Quality Control in Two Multi-Centre Multiple Sclerosis Clinical Trials.

Keltner JL, Cello KE, Balcer LJ, Calabresi PA, Markowitz CE, Werner JS.

Neuroophthalmology. 2011 Mar 20;35(2):57-64. doi: 10.3109/01658107.2011.557760. eCollection 2011.

11.

Fingolimod for the treatment of relapsing multiple sclerosis.

Jeffery DR, Markowitz CE, Reder AT, Weinstock-Guttman B, Tobias K.

Expert Rev Neurother. 2011 Feb;11(2):165-83. doi: 10.1586/ern.10.193. Epub 2010 Dec 16. Review.

PMID:
21158700
12.

The current landscape and unmet needs in multiple sclerosis.

Markowitz CE.

Am J Manag Care. 2010 Sep;16(8 Suppl):S211-8. Review.

13.

Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis.

Talman LS, Bisker ER, Sackel DJ, Long DA Jr, Galetta KM, Ratchford JN, Lile DJ, Farrell SK, Loguidice MJ, Remington G, Conger A, Frohman TC, Jacobs DA, Markowitz CE, Cutter GR, Ying GS, Dai Y, Maguire MG, Galetta SL, Frohman EM, Calabresi PA, Balcer LJ.

Ann Neurol. 2010 Jun;67(6):749-60. doi: 10.1002/ana.22005.

14.

An approach to comparing accuracies of two FLAIR MR sequences in the detection of multiple sclerosis lesions in the brain in the absence of gold standard.

Bilello M, Suri N, Krejza J, Woo JH, Bagley LJ, Mamourian AC, Vossough A, Chen JY, Millian BR, Mulderink T, Markowitz CE, Melhem ER.

Acad Radiol. 2010 Jun;17(6):686-95. doi: 10.1016/j.acra.2010.01.019.

PMID:
20457413
15.

Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis.

Burkholder BM, Osborne B, Loguidice MJ, Bisker E, Frohman TC, Conger A, Ratchford JN, Warner C, Markowitz CE, Jacobs DA, Galetta SL, Cutter GR, Maguire MG, Calabresi PA, Balcer LJ, Frohman EM.

Arch Neurol. 2009 Nov;66(11):1366-72. doi: 10.1001/archneurol.2009.230.

PMID:
19901168
16.

Modulation of serum uric acid levels by inosine in patients with multiple sclerosis does not affect blood pressure.

Spitsin S, Markowitz CE, Zimmerman V, Koprowski H, Hooper DC.

J Hum Hypertens. 2010 May;24(5):359-62. doi: 10.1038/jhh.2009.83. Epub 2009 Oct 29.

PMID:
19865105
17.

The treatment of multiple sclerosis with inosine.

Markowitz CE, Spitsin S, Zimmerman V, Jacobs D, Udupa JK, Hooper DC, Koprowski H.

J Altern Complement Med. 2009 Jun;15(6):619-25. doi: 10.1089/acm.2008.0513.

18.

Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity.

Mowry EM, Loguidice MJ, Daniels AB, Jacobs DA, Markowitz CE, Galetta SL, Nano-Schiavi ML, Cutter GR, Maguire MG, Balcer LJ.

J Neurol Neurosurg Psychiatry. 2009 Jul;80(7):767-72. doi: 10.1136/jnnp.2008.165449. Epub 2009 Feb 23.

PMID:
19240050
19.

Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis.

Zaveri MS, Conger A, Salter A, Frohman TC, Galetta SL, Markowitz CE, Jacobs DA, Cutter GR, Ying GS, Maguire MG, Calabresi PA, Balcer LJ, Frohman EM.

Arch Neurol. 2008 Jul;65(7):924-8. doi: 10.1001/archneur.65.7.924.

PMID:
18625859
20.

Relation of vision to global and regional brain MRI in multiple sclerosis.

Wu GF, Schwartz ED, Lei T, Souza A, Mishra S, Jacobs DA, Markowitz CE, Galetta SL, Nano-Schiavi ML, Desiderio LM, Cutter GR, Calabresi PA, Udupa JK, Balcer LJ.

Neurology. 2007 Dec 4;69(23):2128-35. Epub 2007 Sep 19.

PMID:
17881718
21.

Interferon-beta: mechanism of action and dosing issues.

Markowitz CE.

Neurology. 2007 Jun 12;68(24 Suppl 4):S8-11. Review.

PMID:
17562848
22.

Palliative care in amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis.

Elman LB, Houghton DJ, Wu GF, Hurtig HI, Markowitz CE, McCluskey L.

J Palliat Med. 2007 Apr;10(2):433-57. Review.

PMID:
17472516
23.

Treatment of Susac syndrome with gamma globulin and corticosteroids.

Fox RJ, Costello F, Judkins AR, Galetta SL, Maguire AM, Leonard B, Markowitz CE.

J Neurol Sci. 2006 Dec 21;251(1-2):17-22. Epub 2006 Oct 17.

PMID:
17052732
24.

Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25.

Raphael BA, Galetta KM, Jacobs DA, Markowitz CE, Liu GT, Nano-Schiavi ML, Galetta SL, Maguire MG, Mangione CM, Globe DR, Balcer LJ.

Am J Ophthalmol. 2006 Dec;142(6):1026-35. Epub 2006 Oct 13.

25.

Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis.

Fisher JB, Jacobs DA, Markowitz CE, Galetta SL, Volpe NJ, Nano-Schiavi ML, Baier ML, Frohman EM, Winslow H, Frohman TC, Calabresi PA, Maguire MG, Cutter GR, Balcer LJ.

Ophthalmology. 2006 Feb;113(2):324-32. Epub 2006 Jan 10.

PMID:
16406539
26.

Checkerboard fields in multiple sclerosis.

Tamhankar MA, Markowitz CE, Galetta SL.

J Neurol Neurosurg Psychiatry. 2005 Feb;76(2):268. No abstract available.

27.

Neuronal cell injury precedes brain atrophy in multiple sclerosis.

Ge Y, Gonen O, Inglese M, Babb JS, Markowitz CE, Grossman RI.

Neurology. 2004 Feb 24;62(4):624-7.

PMID:
14981182
28.

Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite.

Balcer LJ, Baier ML, Cohen JA, Kooijmans MF, Sandrock AW, Nano-Schiavi ML, Pfohl DC, Mills M, Bowen J, Ford C, Heidenreich FR, Jacobs DA, Markowitz CE, Stuart WH, Ying GS, Galetta SL, Maguire MG, Cutter GR.

Neurology. 2003 Nov 25;61(10):1367-73.

PMID:
14638957
29.

The "double panda sign" in Wilson's disease.

Jacobs DA, Markowitz CE, Liebeskind DS, Galetta SL.

Neurology. 2003 Oct 14;61(7):969. No abstract available.

PMID:
14557570
30.

Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: evidence for different clinical cohorts initial observations.

Gonen O, Moriarty DM, Li BS, Babb JS, He J, Listerud J, Jacobs D, Markowitz CE, Grossman RI.

Radiology. 2002 Oct;225(1):261-8.

PMID:
12355014
31.

Self-reported visual dysfunction in multiple sclerosis: new data from the VFQ-25 and development of an MS-specific vision questionnaire.

Ma SL, Shea JA, Galetta SL, Jacobs DA, Markowitz CE, Maguire MG, Balcer LJ.

Am J Ophthalmol. 2002 May;133(5):686-92.

PMID:
11992867
32.

Effect of opioid receptor antagonism on proopiomelanocortin peptide levels and gene expression in the hypothalamus.

Markowitz CE, Berkowitz KM, Jaffe SB, Wardlaw SL.

Mol Cell Neurosci. 1992 Jun;3(3):184-90.

PMID:
19912859
33.

Supplemental Content

Loading ...
Support Center